Biosimilars in Treatment of Multiple Sclerosis in Iran.

Abdorreza Naser Moghadasi

doi:10.34172/aim.2021.115

Abdorreza Naser Moghadasi

Open Access

https://doi.org/10.34172/aim.2021.115

Copy DOI

Abstract

Biological drugs are manufactured via some changes made to the living organisms by genetic engineering. Notably, biological drugs are very expensive and their importation can impose economic pressure, especially on poorer countries. Thereafter, manufacturing these drugs has been considered by policymakers in many countries, resulting in the production of biosimilars. Iran requires a wide range of biological drugs due to the growing number of patients with multiple sclerosis. On the other hand, the poor economic situation of Iran due to repeated sanctions has had a great impact on the health care system, which has prevented the allocation of sufficient financial resources in this regard. Therefore, manufacturing biosimilar drugs due to their lower cost has received much attention in various fields of treatment.

Highlights

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that mainly affects young people
This study showed no difference between these two drugs in terms of complication rate, magnetic resonance imaging (MRI), and clinical results.[6]
Biosimilars are widely used in Iran

Summary

Introduction

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that mainly affects young people. Biological drugs are very expensive and can impose economic pressure, especially on poorer countries Manufacturing these drugs has been considered by policymakers in many countries, resulting in the production of biosimilars.[3] Biosimilars are biological drugs that are very similar in structure, function, side effects, and efficacy to the prototype.[3]. Iran needs to use a wide range of biological drugs due to the growing number of MS patients In this regard, manufacturing biosimilar drugs due to their lower cost has received much attention in various fields of treatment.[3]. Biosimilars in Treatment of MS in Iran During past years, several biosimilar drugs have been produced by Iranian companies in Iran By introducing these drugs, this section discusses studies performed on their different aspects. Abolfazli et al observed no difference in quality of life between CinnoVex and Avonex recipients after 30 months of follow-up.[9]

Shahkarami et al compared the levels of neutralizing

Findings

Discussion